ClinicalTrials.gg
RecruitingNCT07267455Updated Dec 5, 2025

Efficacy Analysis of Personalized-Target Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Tinnitus: A Single-Center, Single-Blind Randomized Clinical Trial

An interventional study of continuous theta burst stimulation in Chronic Tinnitus, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tinnitus with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Tinnitus · China.

Planned enrollment
16th of 27
116 · median 120
Started
2025
with 1 other
No phase
27 of 32
16 open now
Primary completion
2030-01
later than 14 of 17 live
Registered
25th of 32
by date
Lead sponsor
6 of 32
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 32 studies in Tinnitus with a site in China, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 27 with no phase, reaches primary completion later than 14 of the 17 other live ones, and was the 25th registered.

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

Browse Tinnitus studies →

Open to participants now

18 of the 32 studies in Tinnitus with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tinnitus with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of personalized-target transcranial magnetic stimulation (TMS) in the treatment of chronic subjective tinnitus. The study aims to determine whether stimulation at individualized auditory cortex targets, identified by resting-state functional MRI, provides greater therapeutic benefit compared with conventional TMS targets.

A total of 116 patients with chronic tinnitus will be recruited and randomly assigned to receive either personalized-target TMS or traditional-target TMS for five consecutive days.

The main questions this study aims to answer are:

Does personalized-target TMS improve tinnitus-related symptoms more effectively than traditional-target TMS?

Is personalized-target TMS a safe and tolerable intervention for patients with chronic tinnitus?

Researchers will compare the changes in tinnitus-related clinical rating scales between the two groups, including the Tinnitus Handicap Inventory (THI), Visual Analog Scale (VAS), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), and Pittsburgh Sleep Quality Index (PSQI).

Participants will:

Receive continuous theta burst stimulation (cTBS) targeting the left auditory cortex region showing the strongest functional connectivity with the parahippocampal gyrus, identified through resting-state fMRI.

Undergo three cTBS sessions per day (600 pulses per session, 1,800 pulses total daily) for five days.

Complete follow-up assessments at 1 month and 3 months after treatment to evaluate the durability of clinical effects.

This study will also assess treatment adherence, safety outcomes, and potential predictors of therapeutic response to personalized-target TMS.

03

Conditions studied

  • Chronic Tinnitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Patients with tinnitus as the main complaint: Patients perceive subjective sounds in the ears or deep within the skull in the absence of internal or external acoustic stimulation.

    2.Patients with chronic tinnitus who meet the conditions including tinnitus duration of more than 6 months, THI (tinnitus handicap inventory) score ≥ 38, and no response to conventional drug treatment.

    3.Outpatients of Sun Yat-sen University Sun Yat-sen Memorial Hospital who can receive continuous 5-day cTBS treatment.

    4.Tinnitus frequency ranges from 125 Hz to 8000 Hz. 5.Aged 18-70 years.

Exclusion criteria

Exclusion Criteria:

  • 1.Patients with tinnitus associated with the following conditions: conductive hearing loss, a history of middle ear surgery, pulsatile tinnitus caused by vascular malformations, or Meniere's disease.

    2.A history of any of the following: head trauma, central nervous system diseases, psychiatric disorders, or substance abuse.

    3.Pregnancy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Personalized-Target TMS Group

    Participants receive continuous theta burst stimulation (cTBS) targeting the individualized auditory cortex region showing the strongest functional connectivity with the left parahippocampal gyrus, as identified by resting-state fMRI. Each participant receives 600 pulses per session, 3 sessions per day (total 1,800 pulses daily) for 5 consecutive days.

    Device: continuous theta burst stimulation

  • Active comparator
    conventional auditory cortex site

    Participants receive continuous theta burst stimulation (cTBS) targeting the left auditory cortex at EEG 10-20 system site CP5, as used in prior tinnitus studies. Stimulation parameters are identical to the experimental group (600 pulses per session, 3 sessions per day, for 5 consecutive days).

    Device: continuous theta burst stimulation

Interventions

  • Devicecontinuous theta burst stimulation

    This study evaluates personalized-target and conventional-target transcranial magnetic stimulation (TMS) for the treatment of chronic subjective tinnitus. Participants will receive continuous theta burst stimulation (cTBS) applied to the left auditory cortex. For the personalized-target arm, stimulation sites are individualized based on resting-state fMRI, targeting the region of strongest functional connectivity with the parahippocampal gyrus. For the conventional-target arm, stimulation is delivered at the CP5 site. Each session consists of 600 pulses, delivered in three sessions per day (1,800 pulses daily) for five consecutive days.

06

What researchers measure

Primary outcomes

  1. the effective rate of chronic tinnitus relief in the two groups of patients before treatment and 5 days after treatment

    It is defined as follows: Effective rate = \[(Number of patients in each group who completed the 5-day treatment and had a Tinnitus Handicap Inventory (THI) score decrease of ≥ 7 points from the baseline) / (Total number of patients in each group who completed the 5-day treatment)\] × 100%. The assessment time points for this outcome are before treatment (baseline) and 5 days after treatment.

    Time frame: From enrollment to the end of treatment at 5 days

Secondary outcomes

  1. Tinnitus Loudness

    Change in tinnitus loudness, assessed using the Visual Analog Scale (VAS), which ranges from 0 (no tinnitus) to 10 (worst tinnitus imaginable).

    Time frame: Baseline, post-treatment (day 5), 1-month follow-up, 3-month follow-up

  2. Anxiety Symptoms

    Change in anxiety symptoms, assessed using the Beck Anxiety Inventory (BAI), a self-reported questionnaire measuring severity of anxiety.

    Time frame: Baseline, post-treatment (day 5), 1-month follow-up, 3-month follow-up

  3. Depressive Symptoms

    Change in depressive symptoms, assessed using the Beck Depression Inventory (BDI), a self-reported scale evaluating severity of depression.

    Time frame: Baseline, post-treatment (day 5), 1-month follow-up, 3-month follow-up

  4. Sleep Quality

    Change in sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI), which evaluates sleep quality and disturbances over a 1-month period.

    Time frame: Baseline, post-treatment (day 5), 1-month follow-up, 3-month follow-up

  5. Long-term Efficacy of Tinnitus Relief

    Effective rate = \[(Number of patients in each group who completed the 5-day treatment and had a Tinnitus Handicap Inventory (THI) score decrease of ≥ 7 points from the baseline) / (Total number of patients in each group who completed the 5-day treatment)\] × 100%. The assessment time points for this outcome are before treatment (baseline) and 1 month, 3 month after treatment.

    Time frame: 1-month follow-up, 3-month follow-up

  6. EEG Changes

    Changes in electroencephalography (EEG) measures associated with tinnitus and cortical activity, assessed before treatment, after 5 days of intervention, and at 1-month and 3-month follow-ups.

    Time frame: Baseline (pre-treatment), post-treatment (day 5), 1-month follow-up, 3-month follow-up

  7. MRI Changes

    Changes in brain structure and functional connectivity assessed using magnetic resonance imaging (MRI), including the auditory cortex and related networks. MRI is performed at baseline (pre-treatment) and at 1-month follow-up to evaluate early post-treatment neural changes.

    Time frame: Baseline (pre-treatment), 1-month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) from this study will not be shared due to privacy concerns and ethical restrictions related to patient confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2030, 53 months after the start.

Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 53 months is above that.

Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Jan 2030
CompletionEst.
Aug 2030
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07267455
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Aug 1, 2025
Primary completion
Jan 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Dec 5, 2025

Study contacts

Yuexin Cai, Doctor
Contact
caiyx25@mail.sysu.edu.cn
86+13825063663
Qianhui Xu, MD
Contact
xuqh9@mail2.sysu.edu.cn
86+13719908396
Yuexin Cai, Doctor
study chair · Yuexin Cai, Doctor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion